ストックスクリーナーアプリを入手
1.78
0.00%
0.00
アフターアワーズ：
1.75
-0.03
-1.69%
前日終値:
$1.78
開ける：
$1.8
24時間の取引高:
997.80K
Relative Volume:
0.51
時価総額：
$278.31M
収益：
$127.04M
当期純損益:
$-110.56M
株価収益率:
-1.5214
EPS:
-1.17
ネットキャッシュフロー:
$-60.33M
1週間 パフォーマンス:
-6.81%
1か月 パフォーマンス:
-16.04%
6か月 パフォーマンス:
-31.80%
1年 パフォーマンス:
+137.18%
1日の値動き範囲:
$1.75
$1.85
1週間の範囲:
$1.70
$1.885
52週間の値動き範囲:
$0.50
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
名前
Heron Therapeutics Inc
セクター
電話
(858) 251-4400
住所
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-05-27 | 開始されました | Guggenheim | Buy |
| 2020-02-20 | 繰り返されました | Needham | Buy |
| 2019-01-16 | 繰り返されました | Needham | Buy |
| 2018-04-05 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 繰り返されました | Mizuho | Buy |
| 2018-03-01 | 繰り返されました | Needham | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Outperform |
| 2017-09-27 | 開始されました | Northland Capital | Outperform |
| 2017-02-27 | 開始されました | Needham | Buy |
| 2016-10-26 | 開始されました | Aegis Capital | Buy |
| 2016-09-06 | 再開されました | Lake Street | Buy |
| 2016-05-03 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-12-10 | 開始されました | Lake Street | Buy |
| 2015-09-23 | 繰り返されました | Leerink Partners | Outperform |
| 2015-09-02 | 開始されました | BofA/Merrill | Buy |
| 2015-08-03 | 繰り返されました | Brean Capital | Buy |
| 2015-06-30 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2015-06-19 | 繰り返されました | Leerink Partners | Outperform |
| 2014-08-07 | 開始されました | Noble Financial | Buy |
すべてを表示
Heron Therapeutics Inc (HRTX) 最新ニュース
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - StockTitan
Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt - The Globe and Mail
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - Longview News-Journal
SG Americas Securities LLC Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Antinauseants Market Insights, Forecast to 2031Heron - openPR
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat
Heron Therapeutics Inc (HRTX) deserves deeper analysis - US Post News
Investor’s Toolkit: Key Ratios for Assessing Heron Therapeutics Inc (HRTX)’s Performance - The Dwinnex
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Congress Park Capital LLC - MarketBeat
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - The Malaysian Reserve
Its Stock Has Paid Off Big Time For Heron Therapeutics Inc - SETE News
AQR Capital Management LLC Raises Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc Inc. (HRTX) Price Performance: The Role of Supply and Demand - The InvestChronicle
Can you now get a good deal on Heron Therapeutics Inc’s shares? - US Post News
Squarepoint Ops LLC Purchases 286,160 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Buying Buzz: Heron Therapeutics Inc [HRTX] EVP, Chief Development Officer Forbes William P purchases 25,000 shares of the company – Knox Daily - Knox Daily
HRTX’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
When Can We Expect A Profit From Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Simply Wall St
Get in on Heron Therapeutics Inc’s (HRTX) buy-in window today! - SETE News
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability - Yahoo Finance
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Marshall Wace LLP - Defense World
Heron Therapeutics Inc’s results are impressive - US Post News
Marshall Wace LLP Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Market Momentum Report: Heron Therapeutics Inc (HRTX)’s Negative Close at 1.99 - The Dwinnex
Clearline Capital LP Sells 1,280,938 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron gains on FDA nod for new Zynrelef application - MSN
Renaissance Technologies LLC Reduces Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics Inc [NASDAQ: HRTX] Sees Decrease in Stock Value - Knox Daily
Renaissance Technologies LLC Lowers Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Needham & Company LLC Reaffirms "Buy" Rating for Heron Therapeutics (NASDAQ:HRTX) - MarketBeat
Adversity is less terrifying than hope: Heron Therapeutics Inc (HRTX) - SETE News
Heron stock gains on FDA nod for Zynrelef method (NASDAQ:HRTX) - Seeking Alpha
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") - PR Newswire
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Rhumbline Advisers - Defense World
Heron Therapeutics Inc (HRTX) stock on the rise: An overview - US Post News
Wealth Alliance Has $112,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Acadian Asset Management LLC Makes New Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
E Fund Management Co. Ltd. Acquires New Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Orchard Capital Management LLC - Defense World
Bank of New York Mellon Corp Purchases 113,655 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Pekin Hardy Strauss Inc. Has $88,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Richmond Brothers Inc. - Defense World
Monitoring Heron Therapeutics Inc (HRTX) after recent insider movements - Knox Daily
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Principal Financial Group Inc. - Defense World
Heron Therapeutics Inc (HRTX) stock: A year of ups and downs - US Post News
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR - GlobeNewswire Inc.
Holdings of Heron Therapeutics Inc (HRTX) are aligned with the stars - SETE News
Market Highlights: Heron Therapeutics Inc (HRTX) Ends on a High Note at 1.87 - The Dwinnex
Heron Therapeutics Inc (HRTX) 財務データ
収益
当期純利益
現金流量
EPS
5.11%
0.50%
大文字化:
|
ボリューム (24 時間):